Immune signatures of chronic inflammatory human diseases driving cancer

The laboratory of Mathias Heikenwälder aims at understanding the different immune signatures of chronic inflammatory human diseases driving cancer - with the final aim to generate appropriate mouse models used for pre-clinical research and translation into the clinic. A focus of the laboratory is to understand how inflammation (induced by life-style factors or pathogens (e.g. viruses or bacteria)) drives cancer in regenerative organs (such as the liver or the gastrointestinal tract).

A particular research focus of the Mathias Heikenwälder laboratory is the elucidation of the molecular and cellular mechanisms causing fatty liver disease, subsequent inflammation,  tissue damage (called non-alcoholic steatohepatitis (NASH)) and resulting liver cancer. Life-style related factors have contributed to the fact that today liver cancer is the 4th most common cause for cancer-related death and the fastest rising cancer in the world.

Mainly caused by a sedentary life style and hypercaloric nutrition, NASH is one of the leading causes of chronic liver disease with the potential of evolving towards end-stage liver disease and hepatocellular carcinoma (HCC), even in the absence of cirrhosis. Every third American and European citizen has a fatty liver. Apart from becoming an increasingly prevalent indication for liver transplantation in cirrhotic and HCC patients, its burden on the healthcare system is also exerted by the increased number of non-cirrhotic NASH patients. Currently, there are no efficient therapies available that would either prevent NASH, revert fibrosis or block NASH to HCC transition.

The Heikenwälder laboratory focuses on comparative studies of human and animal model tissues, recapitulating human disease on a histo-pathological and pathophysiological level, engaging in classical molecular biology techniques complemented with sophisticated ways to receive as much information from tissue samples through histology (e.g. light microscopy/ immune fluorescence/ FISH/ in situ hybridization), other in vivo imaging techniques (e.g. MRI) as well as through FACS analyses for tissue homogenates. At the same time the systemic functional effects of pathologies and the interplay between several affected non-lymphoid organs and the immune system is investigated. Testing several therapeutic compounds in a single but also combinatorial fashion is executed in the Heikenwälder laboratory employing established and stratified pre-clinical mouse models.

In the past the Heikenwälder laboratory has elucidated how the adaptive and innate immune system drives NASH and affects therapy response (e.g. in the context of systemic liver cancer therapy) - which has led to the generation of drugs that are currently tested for clinical use. Mathias Heikenwälder is an elected member of the Leopoldina, most highly cited researcher world-wide from 2018-2022 (“Cross Topic” Web of Science) and has received several prestigious grants (ERC-Stg, ERC-CoG; ERC-POC) and awards (Prof. Max Cloetta award, Götz prize, Walther and Christine Richtzenhain award, Prof. Hans Peter Hofschneider award). In 2022 he has received the German Cancer award.  

Prof. Mathias Heikenwälder is a trained molecular biologist, with expertise in immunology and a strong link to translational research evoked by 10 years of work and expertise in a Pathology Institution (Clinical Pathology, University Hospital Zurich). Since October 2015 he is Department head at the German Cancer Research Center (DKFZ) in Heidelberg focusing on the link between chronic inflammation and cancer. Since October 2022 he is director of the M3 Research Center, University Tübingen. Prof. Heikenwälder publishes his work in high-ranking journals and has established himself as an international leader in the field of liver cancer. Mathias Heikenwälder is the third most frequently cited German-speaking researcher in the field of cell biology in the last years and was one of the Highly Cited Researchers (Cross Fields) (Web of Science Group) in 2019, 2020, 2021 and 2022. Not only have his publications been widely cited by the research community, but they have also shifted fatty liver and liver cancer research in new directions - relevant to the day-to-day management of patients with fatty liver or liver cancer.

  • Division of Chronic Inflammation and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Im Neuenheimer Feld 280, 69120 Heidelberg, Germany

  • Cluster of Excellence “Image-guided and functionally instructed tumor therapies" (iFIT), University of Tübingen, Germany

  • Cluster of Excellence "Controlling Microbes to Fight Infections" (CMFI), University of Tübingen, Germany

The research focus of our laboratory is to investigate the role of chronic inflammation induced tissue damage and cancer caused by different environmental triggers:

  • Chronic infections with viruses, bacteria and their role in affecting the tumor directly (intratumoral) or the tumor microenvironment
  • Unhealthy life style (hyper caloric diet in combination with a sedentary life style; chronic smoking or alcohol abuse) and interconnected aberrant metabolism or chronic inflammation 
  • Generation of therapeutic concepts (e.g. combinatorial therapies; identification of novel targets) and life-style interventions (e.g. intermittent fasting)

 

NASH
non-alcoholic steatohepatitis
inflammation
driving cancer in regenerative organs
HCC
hepatocellular carcinoma

Selected publications

  • 2024

    Single-cell profiling of intrahepatic immune cells reveals an expansion of tissue-resident cytotoxic CD4+ T lymphocyte subset associated with pathogenesis of alcoholic-associated liver diseases

    Gao C, Wang S, Xie X, Ramadori P, Li X, Liu X, Ding X, Liang J, Xu B, Feng Y, Tan X, Wang H, Zhang Y, Zhang H, Zhang T, Mi P, Li S, Zhang C, Yuan D, Heikenwalder M*, Zhang P*.

    Cell Mol Gastroenterol Hepatol. 2024 Sep 28:101411. doi: 10.1016/j.jcmgh.2024.101411. Online ahead of print.

    *Co-last co-corresponding

    PubMed
  • 2024

    TNF compromises intestinal bile-acid tolerance dictating colitis progression and limited infliximab response

    Zheng M, Zhai Y, Yu Y, Shen J, Chu S, Focaccia E, Tian W, Wang S, Liu X, Yuan X, Wang Y, Li L, Feng B, Li Z, Guo X, Qiu J, Zhang C, Hou J, Sun Y, Yang X, Zuo X*, Heikenwalder M*, Li Y*, Yuan D*, Li S*.

    Cell Metab. 2024 Sep 3;36(9):2086-2103.e9. doi: 10.1016/j.cmet.2024.06.008. Epub 2024 Jul 5.

    *Co-corresponding

    PubMed
  • 2024

    HBV-related HCC development in mice is STAT3 dependent and indicates an oncogenic effect of HBx

    Ringelhan M, Schuehle S, van de Klundert M, Kotsiliti E, Plissonnier ML, Faure-Dupuy S, Riedl T, Lange S, Wisskirchen K, Thiele F, Cheng CC, Yuan D, Leone V, Schmidt R, Hünergard J, Geisler F, Unger K, Algül H, Schmid RM, Rad R, Wedemeyer H, Levrero M, Protzer U*, Heikenwalder M*.

    JHEP Rep. 2024 Jun 6;6(10):101128. doi: 10.1016/j.jhepr.2024.101128. eCollection 2024 Oct.

    *Co-last co-corresponding

    PubMed
  • 2024

    Ribosomal S6 kinase 1 regulates inflammaging via the senescence secretome.

    Gallage S, Irvine EE, Barragan Avila JE, Reen V, Pedroni SMA, Duran I, Ranvir V, Khadayate S, Pombo J, Brookes S, Heide D, Dharmalingham G, Choudhury AI, Singh I, Herranz N, Vernia S, Heikenwalder M*, Gil J*, Withers DJ*.

    Nat Aging. 2024 Aug 29. doi: 10.1038/s43587-024-00695-z. Online ahead of print.

    *Co-last co-corresponding

    PubMed
  • 2024

    A 5:2 intermittent fasting regimen ameliorates NASH and fibrosis and blunts HCC development via hepatic PPARα and PCK1.

    Gallage S, Ali A, Barragan Avila JE, Seymen N, Ramadori P, Joerke V, Zizmare L, Aicher D, Gopalsamy IK, Fong W, Kosla J, Focaccia E, Li X, Yousuf S, Sijmonsma T, Rahbari M, Kommoss KS, Billeter A, Prokosch S, Rothermel U, Mueller F, Hetzer J, Heide D, Schinkel B, Machauer T, Pichler B, Malek NP, Longerich T, Roth S, Rose AJ, Schwenck J, Trautwein C, Karimi MM, Heikenwalder M.

    Cell Metab. 2024 Jun 4;36(6):1371-1393.e7. doi: 10.1016/j.cmet.2024.04.015. Epub 2024 May 7.

    PubMed
  • 2023

    Intestinal B-cells license metabolic T-cell activation in NASH microbiota/antigen-independently and contribute to fibrosis by IgA-FcR signalling

    Kotsiliti E, Leone V, Schuehle S, Govaere O, Li H, Wolf MJ, Horvatic H, Bierwirth S, Hundertmark J, Inverso D, Zizmare L, Sarusi-Portuguez A, Gupta R, O'Connor T, Giannou AD, Shiri AM, Schlesinger Y, Beccaria MG, Rennert C, Pfister D, Öllinger R, Gadjalova I, Ramadori P, Rahbari M, Rahbari N, Healy M, Fernández-Vaquero M, Yahoo N, Janzen J, Singh I, Fan C, Liu X, Rau M, Feuchtenberger M, Schwaneck E, Wallace SJ, Cockell S, Wilson-Kanamori J, Ramachandran P, Kho C, Kendall TJ, Leblond AL, Keppler SJ, Bielecki P, Steiger K, Hofmann M, Rippe K, Zitzlesberger H, Weber A, Malek N, Lüdde T, Vucur M, Augustin HG, Flavell R, Parnas O, Rad R, Pabst O, Henderson NC, Huber S, Macpherson A, Knolle P, Claasen M, Geier A, Trautwein C, Unger K, Elinav E, Waisman A, Abdullah Z, Haller D, Tacke F, Anstee QM, Heikenwalder M.

    Intestinal B-cells license metabolic T-cell activation in NASH microbiota/antigen-independently and contribute to fibrosis by IgA-FcR signalling.

    Journal of Hepatology 2023 May 9:S0168-8278(23)00325-2. doi: 10.1016/j.jhep.2023.04.037. Epub ahead of print. PMID: 37224925. IF: 31

    PubMed
  • 2021

    XCR1+ type 1 conventional dendritic cells drive liver pathology in Non-Alcoholic Steatohepatitis

    Aleksandra Deczkowska, Eyal David, Pierluigi Ramadori, Dominik Pfister, Michal Safran, Baoguo Li, Amir Giladi, Diego Adhemar Jaitin, Oren Barboy, Merav Cohen, Ido Yofe, Chamutal Gur, Shir Shlomi-Loubaton, Sandrine Henri, Yousuf Suhail, Mengjie Qiu, Shing Kam, Hila Hermon, Eylon Lahat, Gil Ben-Yakov, Oranit Cohen-Ezra, Yana Davidov, Mariya Likhter, David Goitein8,10, Susanne Roth, Achim Weber, Bernard Malissen, Assaf Weiner, Ziv Ben-Ari, Mathias Heikenwalder*, Eran Elinav*, Ido Amit*.

    Nature Medicine, 2021 Jun;27(6):1043-1054. IF: 53,4

    *Co-last, co-corresponding author

    PubMed
  • 2021

    NASH limits anti-tumour surveillance in immunotherapy-treated HCC

    Dominik Pfister, Nicolás Gonzalo Núñez, Roser Pinyo, Olivier Govaere, Matthias Pinter, Marta Szydlowska, Revant Gupta, Mengjie Qiu, Aleksandra Deczkowska, Assaf Weiner, Florian Müller, Ankit Sinha, Ekaterina Friebel, Thomas Engleitner, Daniela Lenggenhager, Kristin Stirm, Jan Kosla, Suhail Youssuf, Michael Dudek, Eleni Kotsiliti, Valentina Leone, Donato Inverso, Indrabahadur Singh, Florian Castet, Carla Montironi, Philipp K. Haber, Dina Tiniakos, Pierre Bedossa, Simon Cockell, Ramy Younes, Michele Vacca, Fabio Marra, Jörn M. Schattenberg, Michael Allison, Elisabetta Bugianesi, Vlad Ratziu, Tiziana Pressiani, Antonio D'Alessio, Nicola Personeni, Lorenza Rimassa, Ann K. Daly, Bernhard Scheiner, Katharina Pomej, Martha M. Kirstein, Arndt Vogel, Markus Peck-Radosavljevic, Florian Hucke, Fabian Finkelmeier, Oliver Waidmann, Jörg Trojan, Kornelius Schulze, Henning Wege, Sandra Koch, Arndt Weinmann, Marco Bueter, Fabian Rössler, Alexander Siebenhüner, Sara De Dosso, Manfred Jugold, Tom Luedde, Andrea Schietinger, Peter Schirmacher, Hellmut G. Augustin, Adrian Billeter, Beat Müller-Stich, Katharina Wolter, Lars Zender, Henrik E. Mei, Axel Ronald Schulz, Marc Ringelhan, Nisar Malek, Stephan Spahn, Michael Bitzer, Amaia Lujambio, Nuh Rahbari, Jean-Francois Dufour, Thomas U. Marron, Ahmed Kaseb, Masatoshi Kudo, Yi-Hsiang Huang, Ana Teijeiro, Nabil Djouder, Achim Weber, Parice N. Marche, David J. Pinato, Thomas Decaens, Zuzana Macek Jilkova, Roland Rad, Joachim C. Mertens, Kristian Unger, Felix Meissner, Susanne Roth, Manfred Claassen, Quentin M. Anstee, Ido Amit, Burkhard Becher, Percy Knolle, Josep M Llovet*, Mathias Heikenwalder*.

    Nature 2021 Mar 24. doi: 10.1038/s41586-021-03362-0. Online ahead of print.PMID: 33762733 IF: 49,9

    *Co-last, co-corresponding author

    Nature
  • 2020

    Blocking of LTbR-signalling prevents epithelial apoptosis and activates endogenous Wnt-induced lung regeneration.

    Conlon TM, John-Schuster G, Heide D, Pfister D, Lehmann M, Hu Y, Ertüz Z, Lopez MA, Ansari M, Strunz M, Mayr C, Ciminieri C, Costa R, Kohlhepp MS, Guillot A, Günes G, Jeridi A, Funk MC, Beroshvili G, Prokosch S, Hetzer J, Verleden SE, Alsafadi H, Lindner M, Burgstaller G, Becker L, Irmler M, Dudek M, Janzen J, Goffin E, Gosens R, Knolle P, Pirotte B, Stoeger T, Beckers J, Wagner D, Singh I, Theis FJ, de Angelis MH, O'Connor T, Tacke F, Boutros M, Dejardin E, Eickelberg O, Schiller HB, Königshoff M, Heikenwalder M*, Yildirim AÖ*.

    Nature 2020; doi: 10.1038/s41586-020-2882-8. IF: 49,9

    *Co-last, co-corresponding author

    Nature
  • 2019

    Age-Related Gliosis Promotes Central Nervous System Lymphoma through CCL19-Mediated Tumor Cell Retention.

    O´Connor T, Zhou X, Kosla J, Adili A, Garcia Beccaria M, Kotsiliti E, Pfister D, Johlke AL, Sinha A, Sankowski R, Schick M, Lewis R, Dokalis N, Seubert B, Höchst B, Inverso D, Heide D, Zhang W, Weihrich P, Manske K, Wohlleber D, Anton M, Hoellein A, Seleznik G, Bremer J, Bleul S, Augustin HG, Scherer F, Koedel U, Weber A, Protzer U, Förster R, Wirth T, Aguzzi A, Meissner F, Prinz M, Baumann B, Höpken UE, Knolle PA, von Baumgarten L, Keller U, Heikenwalder M.

    Cancer Cell 2019; 36:250-267. IF: 31,74

    Cancer Cell
  • 2019

    Platelet GPIba is a mediator and potential interventional target for NASH and subsequent liver cancer

    Malehmir M, Pfister D, Gallage S, Szydlowska M, Inverso D, Kotsiliti E, Leone V, Peiseler M, Surewaard BGJ, Rath D, Ali A, Wolf MJ, Drescher H, Healy ME, Dauch D, Kroy D, Krenkel O, Kohlhepp M, Engleitner T, Olkus A, Sijmonsma T, Volz J, Deppermann C, Stegner D, Helbling P, Nombela-Arrieta C, Rafiei A, Hinterleitner M, Rall M, Baku F, Borst O, Wilson CL, Leslie J, O'Connor T, Weston CJ, Adams DH, Sheriff L, Teijeiro A, Prinz M, Bogeska R, Anstee N, Bongers MN, Notohamiprodjo M, Geisler T, Withers DJ, Ware J, Mann DA, Augustin HG, Vegiopoulos A, Milsom MD, Rose AJ, Lalor PF, Llovet JM, Pinyol R, Tacke F, Rad R, Matter M, Djouder N, Kubes P, Knolle PA, Unger K, Zender L, Nieswandt B, Gawaz M, Weber A*, Heikenwalder M*.

    Nature Medicine 2019; 25:641-655 IF: 53,4

    *Co-last, co-corresponding author

    Nature Medicine
  • 2018

    Single cell polarity in liquid phase facilitates tumour metastasis

    Lorentzen A, Becker PF, Kosla J, Saini M, Weidele K, Ronchi P, Klein C, Wolf MJ, Geist F, Seubert B, Ringelhan M, Mihic-Probst D, Esser K, Roblek M, Kuehne F, Bianco G, O'Connor T, Müller Q, Schuck K, Lange S, Hartmann D, Spaich S, Groß O, Utikal J, Haferkamp S, Sprick MR, Damle-Vartak A, Hapfelmeier A, Hüser N, Protzer U, Trumpp A, Saur D, Vartak N, Klein CA, Polzer B, Borsig L, Heikenwalder M.

    Nature Communications 2018; 9:887-897. IF: 14,92

    PubMed
  • 2017

    Kupffer-cell derived TNF triggers cholangiocellular tumorigenesis through JNK due to chronic mitochondrial dysfunction and ROS

    Yuan D, Huang S, Berger E, Liu L, Gross N, Heinzmann F, Ringelhan M, Connor TO, Stadler M, Meister M, Weber J, Öllinger R, Simonavicius N, Reisinger F, Hartmann D, Meyer R, Reich M, Seehawer M, Leone V, Höchst B, Wohlleber D, Jörs S, Prinz M, Spalding D, Protzer U, Luedde T, Terracciano L, Matter M, Longerich T, Knolle P, Ried T, Keitel V, Geisler F, Unger K, Cinnamon E, Pikarsky E, Hüser N, Davis RJ, Tschaharganeh DF, Rad R, Weber A, Zender L, Haller D*, Heikenwalder M*.

    Cancer Cell 2017; 31:771-789. IF: 31,74

    *Co-last, co-corresponding author

    Cancer Cell
  • 2017

    Dual Role of Caspase-8 in Triggering and Sensing Proliferation-Associated DNA Damage, a Key Determinant of Liver Cancer Development.

    Boege Y, Malehmir M, Healy ME, Bettermann K, Lorentzen A, Vucur M, Ahuja AK, Böhm F, Mertens JC, Shimizu Y, Frick L, Remouchamps C, Mutreja K, Kähne T, Sundaravinayagam D, Wolf MJ, Rehrauer H, Koppe C, Speicher T, Padrissa-Altés S, Maire R, Schattenberg JM, Jeong JS, Liu L, Zwirner S, Boger R, Hüser N, Davis RJ, Müllhaupt B, Moch H, Schulze-Bergkamen H, Clavien PA, Werner S, Borsig L, Luther SA, Jost PJ, Weinlich R, Unger K, Behrens A, Hillert L, Dillon C, Di Virgilio M, Wallach D, Dejardin E, Zender L, Naumann M, Walczak H, Green DR, Lopes M, Lavrik I, Luedde T, Heikenwalder M*, Weber A*.

    Cancer Cell 2017; 32:342-359. IF: 31,74

    *Co-last, co-corresponding author

    Cancer Cell
  • 2015

    Ectopic lymphoid structures function as microniches for tumor progenitor cells in hepatocellular carcinoma.

    Finkin S, Yuan D, Stein I, Taniguchi K, Weber A, Unger K, Browning JL, Goossens N, Nakagawa S, Gunasekaran G, Schwartz ME, Kobayashi M, Kumada H, Berger M, Pappo O, Rajewsky K, Hoshida Y, Karin M, Heikenwalder M*, Ben-Neriah Y*, Pikarsky E*.

    Nature Immunology 2015; 16:1235-44. IF: 25,60

    *Co-last, co-corresponding author

    Nature Immunology
  • 2014

    Metabolic Activation of Intrahepatic CD8+ T Cells and NKT Cells Causes Nonalcoholic Steatohepatitis and Liver Cancer via Cross-Talk with Hepatocytes

    Wolf MJ, Adili A, Piotrowitz K, Abdullah Z, Boege Y, Stemmer K, Ringelhan M, Simonavicius N, Egger M,Wohlleber D, Lorentzen A, Einer C, Schulz S, Clavel T, Protzer U, Thiele C, Zischka H, Moch H, Tschöp M, Tumanov A, Haller D, Unger K, Karin M, Kopf M, Knolle P, Weber A* and Heikenwalder M*.

    Cancer Cell 2014; 26:549-64. IF: 31,74

    *Co-last, co-corresponding author

    Cancer Cell
  • 2014

    Specific and Nonhepatotoxic Degradation of Nuclear Hepatitis B Virus cccDNA.

    Lucifora J, Xia Y, Reisinger F, Zhang K, Stadler D, Cheng X, Sprinzl MF, Koppensteiner H, Makowska Z, Volz T, Remouchamps C, Chou WM, Thasler WE, Hüser N, Durantel D, Liang TJ, Münk C, Heim MH, Browning JL, Dejardin E, Dandri M, Schindler M, Heikenwalder M*, Protzer U*.

    Science 2014; 343:1221-8. IF: 47,72,

    DOI: 10.1126/science.1243462

    *Co-last, co-corresponding author

    Science
  • 2013

    Intrahepatic myeloid-cell aggregates enable local proliferation of CD8+ T cells and successful immunotherapy against chronic viral liver infection

    Huang LR, Wohlleber D, Reisinger F, Jenne CN, Cheng RL, Abdullah Z, Schildberg FA, Odenthal M, Dienes HP, van Rooijen N, Schmitt E, Garbi N, Croft M, Kurts C, Kubes P, Protzer U, Heikenwalder M*, Knolle PA*.

    Nature Immunology 2013 Jun;14(6):574-83. IF: 25,60

    *Co-last, co-corresponding author

    PubMed
  • 2012

    Endothelial CCR2 signaling induced by colon carcinoma cells enables extravasation via the JAK2-Stat5 and p38MAPK pathway.

    Wolf MJ, Hoos A, Bauer J, Boettcher S, Knust M, Weber A, Simonavicius N, Schneider C, Lang M, Stürzl M, Croner RS, Konrad A, Manz MG, Moch H, Aguzzi A, van Loo G, Pasparakis M, Prinz M, Borsig L*, Heikenwalder M*.

    Cancer Cell 2012 Jul; 10;22(1):91-105. IF: 31,74

    *Co-last, co-corresponding author

    Cancer Cell
  • 2012

    Lymphotoxin β receptor signaling promotes development of autoimmune pancreatitis

    Seleznik GM, Reding T, Romrig F, Saito Y, Mildner A, Segerer S, Sun LK, Regenass S, Lech M, Anders HJ, McHugh D, Kumagi T, Hiasa Y, Lackner C, Haybaeck J, Angst E, Perren A, Balmer ML, Slack E, MacPherson A, Manz MG, Weber A, Browning JL, Arkan MC, Rülicke T, Aguzzi A, Prinz M, Graf R*, Heikenwalder M*.

    Gastroenterology. 2012 Nov;143(5):1361-1374. IF: 22,60

    *Co-last, co-corresponding author

    Gastroenterology
  • 2009

    A lymphotoxin-driven pathway to hepatocellular carcinoma.

    Haybaeck J, Zeller N, Wolf MJ, Weber A, Wagner U, Kurrer MO, Bremer J, Iezzi G, Graf R, Clavien PA, Thimme R, Blum H, Nedospasov SA, Zatloukal K, Ramzan M, Ciesek S, Pietschmann T, Marche PN, Karin M, Kopf M, Browning JL, Aguzzi A, Heikenwalder M.

    Cancer Cell 2009; 16:295-308. IF: 26,6

    Cancer Cell

Reviews

  • 2023

    Role of immune responses in the development of NAFLD-associated liver cancer and prospects for therapeutic modulation

    Yahoo N, Dudek M, Knolle P, Heikenwalder M.

    Journal of Hepatology, 79(2), 538–551.

    PubMed
  • 2022

    A researcher's guide to preclinical mouse NASH models

    Gallage S, Avila JEB, Ramadori P, Focaccia E, Rahbari M, Ali A, Malek NP, Anstee QM, Heikenwalder M.

    Nature Metabolism. 2022 Dec;4(12):1632-1649. IF: 19,86

    Nature Metabolism
  • 2021

    The immunological and metabolic landscape in primary and metastatic liver cancer.

    Li X, Ramadori P, Pfister D, Seehawer M, Zender L, Heikenwalder M.

    Nature Reviews Cancer 2021 Sep;21(9):541-557. IF: 60,71

    Nature Reviews Cancer
  • 2019

    From NASH to HCC: current concepts and future challenges.

    Anstee QM, Reeves HL, Kotsiliti E, Govaere O, Heikenwalder M.

    Nature Reviews Gastroenterology Hepatology 2019; 16(7):411‐428. IF: 46,80

    Nature Reviews Gastroenterology Hepatology
  • 2018

    The immunology of hepatocellular carcinoma.

    Ringelhan M, Pfister D, O'Connor T, Pikarsky E, Heikenwalder M.

    Nature Immunology 2018 Mar; 19(3):222-232. Epub 2018 Jan 29. IF: 25,60

    Nature Immunology
  • 2016

    Immune receptor for pathogenic α-synuclein.

    Jucker M, Heikenwalder M.

    Science 2016; 353(6307):1498‐1499. IF: 47,72

    Science